Temferon
Sponsors
Genenta Science S.p.A., Genenta Science
Conditions
Clear Cell RCCGlioblastoma MultiformeGlioblastoma multiforme (GBM)Multiple MyelomaPatients with locally advanced/metastatic renal cell carcinoma with evidence of disease progression following standard of care treatment
Phase 1
A Study Evaluating Temferon in Patients With Glioblastoma & Unmethylated MGMT
Active, not recruitingNCT03866109
Start: 2019-03-05End: 2026-06-30Target: 27Updated: 2026-02-09
A Phase I/II Study Evaluating Temferon in Multiple Myeloma Patients With Early Relapse After Front Line Therapy (TEM-MM)
TerminatedNCT03875495
Start: 2019-03-06End: 2021-04-02Updated: 2022-01-28
A follow-up study evaluating the long term safety of autologous CD34+-enriched hematopoietic progenitor cells genetically modified with a lentiviral vector encoding for the human interferon-α2 gene previously administered to patients with glioblastoma multiforme
RecruitingCTIS2024-516211-25-00
Start: 2022-10-27Target: 5Updated: 2024-08-26
An open-label phase 1/2 study to evaluate the safety, biological response and efficacy of a single dose of Temferon (autologous CD34+-enriched hematopoietic stem and progenitors cells genetically modified with human Interferon-α2) in patients with metastatic renal cell carcinoma
RecruitingCTIS2024-512898-27-00
Start: 2024-10-22Target: 12Updated: 2025-09-17
A Clinical Gene Therapy Study With Hematopoietic Stem Cells for the Treatment, With Single Dose of Temferon, of Patients Suffering From Metastatic Renal Cell Carcinoma
TerminatedNCT06716853
Start: 2024-10-22End: 2026-01-23Updated: 2026-02-09